Gossamer Bio’s (GOSS) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report released on Friday morning,Benzinga reports. Wedbush currently has a $4.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Thursday, January 30th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Trading Up 11.5 %

NASDAQ GOSS opened at $1.45 on Friday. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The firm’s fifty day moving average price is $1.13 and its 200 day moving average price is $0.97. The company has a market capitalization of $328.58 million, a price-to-earnings ratio of -4.53 and a beta of 1.86. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.55.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). The company had revenue of $9.38 million during the quarter, compared to analysts’ expectations of $7.02 million. On average, sell-side analysts expect that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP purchased a new position in Gossamer Bio during the 3rd quarter worth $67,000. US Bancorp DE purchased a new position in Gossamer Bio during the 3rd quarter worth $39,000. The Manufacturers Life Insurance Company grew its position in Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after purchasing an additional 74,920 shares during the last quarter. Monaco Asset Management SAM grew its position in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after purchasing an additional 1,520,721 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in Gossamer Bio by 30.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after purchasing an additional 442,895 shares during the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.